Suritozole

Suritozole is a pharmacological agent that was under investigation for the treatment of Alzheimer's disease. It is a GABA antagonist, specifically a GABA_A receptor antagonist.

History

Suritozole was developed by the pharmaceutical company Eli Lilly and Company. It was investigated as a potential treatment for Alzheimer's disease, but development was discontinued due to lack of efficacy in clinical trials.

Mechanism of Action

Suritozole acts as a GABA_A receptor antagonist. The GABA_A receptor is a type of GABA receptor that responds to the neurotransmitter gamma-aminobutyric acid (GABA), the chief inhibitory compound in the mature vertebrate central nervous system. By blocking these receptors, suritozole may increase neuronal activity in certain areas of the brain.

Clinical Trials

Clinical trials for suritozole were conducted to evaluate its efficacy in treating Alzheimer's disease. However, the results did not show significant improvement in patients' cognitive function or daily living activities. As a result, development of the drug was discontinued.

See Also

• GABA_A receptor
• Alzheimer's disease
• Eli Lilly and Company

References

Suritozole Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski